TCR-engineered T cells meet new challenges to treat solid tumors: Choice of antigen, T cell fitness, and sensitization of tumor milieu

Andre Kunert*, Trudy Straetemans, Coen Govers, Cor Lamers, Ron Mathijssen, Stefan Sleijfer, Reno Debets*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

76 Citations (Scopus)
18 Downloads (Pure)

Abstract

Adoptive transfer of T cells gene-engineered with antigen-specific T cell receptors (TCRs) has proven its feasibility and therapeutic potential in the treatment of malignant tumors. To ensure further clinical development of TCR gene therapy, it is necessary to target immunogenic epitopes that are related to oncogenesis and selectively expressed by tumor tissue, and implement strategies that result in optimal T cell fitness. In addition, in particular for the treatment of solid tumors, it is equally necessary to include strategies that counteract the immune-suppressive nature of the tumor micro-environment. Here, we will provide an overview of the current status of TCR gene therapy, and redefine the following three challenges of improvement: "choice of target antigen"; "fitness of T cells"; and "sensitization of tumor milieu." We will categorize and discuss potential strategies to address each of these challenges, and argue that advancement of clinical TCR gene therapy critically depends on developments toward each of the three challenges.

Original languageEnglish
Article numberArticle 363
JournalFrontiers in Immunology
Volume4
Issue numberNOV
DOIs
Publication statusPublished - 8 Nov 2013

Fingerprint

Dive into the research topics of 'TCR-engineered T cells meet new challenges to treat solid tumors: Choice of antigen, T cell fitness, and sensitization of tumor milieu'. Together they form a unique fingerprint.

Cite this